News
Key Points Core funds from operations per share fell to $0.55 and down 11.3% year-over-year (Q2 2025 vs Q2 2024). GAAP revenue declined to $188.8 million and last year's figure. Management cut ...
The annualized dividend was raised 5.3% to $2.00 per share, with a dividend coverage ratio of 2.16 times available funds from operations (non-GAAP, AFFO basis). These 10 stocks could mint the next ...
Wayfair's stock surged, but rising risks and stretched valuations suggest caution. See why I recommend taking profits and ...
Has the world's No. 3 cryptocurrency by market value -- up nearly 700% over the trailing-three-year period -- come too far, ...
If financial conditions are restrictive, Wall Street sure hasn’t noticed. Stock indexes hit fresh records this week, and speculative meme stocks are back to mania levels. Meanwhile, smaller businesses ...
Businesses, investors and the Fed are all operating under a cloud of uncertainty from Trump’s tariff policy. The latest moves ...
The big question on most investors' minds is whether it makes more sense to buy dips or sell rips (rallies) following the drop. Veteran analyst Tom Lee, Fundstrat's founder and head of research, ...
Stocks surged Monday, led by tech sector gains, as the market recovered from a steep decline at the end of last week that was sparked by renewed concerns about tariffs and the health of the economy.
Powered by rising margins, global growth, and confidence from management, this sleep tech stock is turning heads again. The post ResMed share price is on watch for all-time highs appeared first on The ...
9h
HotCopper on MSNASX Market Open: Yesterday Wall Street's worst since May, today it's best – and Oz follows on | Aug 5
Australian shares may have largely shrugged off Wall Street’s nosedive yesterday, but now that U.S. indexes are surging back into the green, it looks like the ASX 200 is fairly happy to play follow ...
StockStory.org on MSN10h
Kyndryl (NYSE:KD) Misses Q2 Sales Targets, Stock Drops 13%
IT infrastructure services provider Kyndryl (NYSE:KD) in Q2 CY2025, with sales flat year on year at $3.74 billion. Next ...
StockStory.org on MSN10h
BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Strong Q2 Numbers, Stock Soars
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results , with sales up 15.9% year on year to $825.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results